Document is current
Any future updates will be listed below
-
Authors
Beato-Zambrano, Carmen https://orcid.org/0000-0002-1349-2652
Nogues, Xavier https://orcid.org/0000-0002-5537-1859
Ramírez-Merino, Natalia https://orcid.org/0009-0002-7838-967X
Librizzi, María Soledad https://orcid.org/0009-0008-1799-9048
Castañeda, Santos https://orcid.org/0000-0002-7748-853X
Etxebarria Foronda, Iñigo https://orcid.org/0000-0003-2426-5428
Henao-Carrasco, Fernando https://orcid.org/0000-0003-3819-9572
Puente, Javier https://orcid.org/0000-0002-6910-1331
Gurruchaga Sotés, Ibon https://orcid.org/0000-0003-2519-8079
Martínez-Díaz-Guerra, Guillermo https://orcid.org/0000-0001-9498-5979
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica (Funding of the writing of the manuscript)
SEIOMM (Funding of the writing of the manuscript)
- License Information
-
More Information
Article History
Received: 21 January 2026
Accepted: 22 January 2026
First Online: 17 February 2026
Declarations
:
: Carmen Beato-Zambrano has received honoraria for lectures and participation on advisory boards from AstraZeneca, Bristol Myers Squibb, Laboratorios Farmacéuticos ROVI and LEO Pharma; and travel support from Amgen. Xavier Nogués has received honoraria for lectures and participation on advisory boards from Amgen, UCB, Geden-Richter and Theramex. Natalia Ramírez-Merino has received travel support from F. Hoffmann-La Roche Ltd and Pfizer Inc. María Soledad Librizzi has received travel support from UCB Pharma and Amgen and has received honoraria for lectures from Theramex, UCB Pharma and Amgen. Santos Castañeda has received travel support from Amgen, Eli Lilly and Company, Pfizer Inc. and UCB Pharma; and fees for participation on advisory boards for Amgen, Gedeon Richter Plc, Sandoz, STADA Arzneimittel AG and UCB Pharma. Iñigo Etxebarria Foronda declares that he has no conflicts of interest associated with this work . Fernando Henao-Carrasco has received fees for participating in advisory boards from AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, Lilly, and Roche. Javier Puente has received research grants from F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., Pfizer Inc. and Merck KGaA (Darmstadt, Germany); honoraria for lectures and participation on advisory boards from AstraZeneca, Bayer AG, Eisai Co., Ltd., Ipsen, Janssen (Johnson & Johnson), Novartis Pharma AG, MSD (Merck & Co., Inc., Rahway, New Jersey, USA), Pfizer Inc., Gilead Sciences, Inc., Bristol Myers Squibb, Laboratorios Farmacéuticos ROVI and Merck KGaA (Darmstadt, Germany); and travel support from Janssen, Merck KGaA (Darmstadt, Germany), Ipsen and Pfizer Inc. Ibon Gurruchaga Sotés has received honoraria for lectures from GlaxoSmithKline, Bristol Myers Squibb and MSD (Merck & Co., Inc., Rahway, New Jersey, USA); and travel support from Merck KGaA (Darmstadt, Germany), Bristol Myers Squibb, MSD (Merck & Co., Inc., Rahway, New Jersey, USA), Pierre Fabre and Ipsen. Guillermo Martínez-Díaz-Guerra has received travel support from UCB Pharma, Amgen and Theramex; and fees for participation on advisory boards for UCB Pharma, Amgen and Italfarmaco S.p.A.
: This article is a review of previously published studies and does not contain any new studies with human participants or animals performed by any of the authors.
